Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Discovery Medicine|October 28, 2011
MicroRNAs in chromosomal translocation-associated solid tumors: learning from sarcomasFilemon Dela Cruz, Igor MatushanskyOncotarget|May 31, 2012
Solid tumor differentiation therapy - is it possible?Filemon Dela Cruz, Igor MatushanskyDifferentiation; Research in Biological Diversity|March 13, 2012
A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defectsFilemon Dela Cruz, Melissa Terry, Igor MatushanskyCancer Investigation|January 17, 2013
Chemotherapy use in elderly patients with soft tissue sarcoma: a population-based studyIgor Matushansky, Filemon Dela Cruz, Beverly J Insel, et al.Scientific Reports|August 3, 2017
Pediatric Sarcoma Data Forms a Unique Cluster Measured via the Earth Mover's DistanceYongxin Chen, Filemon Dela Cruz, Romeil Sandhu, et al.Scientific Reports|January 4, 2024
Dynamic network curvature analysis of gene expression reveals novel potential therapeutic targets in sarcomaRena Elkin, Jung Hun Oh, Filemon Dela Cruz, et al.Annals of the New York Academy of Sciences|November 15, 2006
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)Paul A Fitzgerald, Robert E Goldsby, John P Huberty, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 15, 2011
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimenPrakash Satwani, Monica Bhatia, James H Garvin, et al.Biorxiv : the Preprint Server for Biology|February 27, 2026
SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsAngelo Taglialatela, Jina Lee, Benura Azeroglu, et al.Genes & Development|July 14, 2026
SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsAngelo Taglialatela, Jina Lee, Benura Azeroglu, et al.Pageof 2